Table II.
Correlation between IMP3 expression and the clinicopathological features of non-small cell lung cancer.
| IMP3 protein expression, n (%) | ||||
|---|---|---|---|---|
|
|
||||
| Variables | +/++ | − | χ2 | P-value |
| Age, years | 0.458 | 0.500 | ||
| <62 | 66 (72.5) | 25 (27.5) | ||
| ≥62 | 73 (76.8) | 22 (23.2) | ||
| Gender | 2.624 | 0.106 | ||
| Male | 79 (70.5) | 33 (29.5) | ||
| Female | 60 (81.1) | 14 (18.9) | ||
| Tumor size, cm | 6.214 | 0.013a | ||
| ≤3 | 51 (65.4) | 27 (34.6) | ||
| >3 | 88 (81.5) | 20 (18.5) | ||
| Differentiation | 19.170 | 0.000b | ||
| Well | 22 (51.2) | 21 (48.8) | ||
| Moderately | 67 (77.0) | 20 (23.0) | ||
| Poorly | 50 (89.3) | 6 (10.7) | ||
| Pathological subtype | 1.018 | 0.314 | ||
| SCC | 68 (78.2) | 19 (21.8) | ||
| AC | 71 (71.7) | 28 (28.3) | ||
| Clinical stage | 20.761 | 0.000b | ||
| I–II | 59 (60.8) | 38 (39.2) | ||
| III–IV | 80 (89.9) | 9 (10.1) | ||
| LN metastasis | 8.331 | 0.004b | ||
| Positive | 84 (83.2) | 17 (16.8) | ||
| Negative | 55 (64.7) | 30 (35.3) | ||
| CEA level | 0.037 | 0.849 | ||
| Normal | 54 (74.0) | 19 (26.0) | ||
| Increased | 85 (75.2) | 28 (24.8) | ||
| Smoking status | 0.364 | 0.547 | ||
| Yes | 94 (73.4) | 34 (26.6) | ||
| No | 45 (77.6) | 13 (22.4) | ||
Statistical analyses were performed using Pearson χ2 tests.
a
P<0.05 and
b
P<0.01.
IMP3, insulin-like growth factor II mRNA-binding protein 3; SCC, squamous cell carcinoma; AC, adenocarcinoma; CEA, carcinoembryonic antigen.